Abstract
Background
Both proinflammatory cytokines and oxidative stress are considered an imbalance between the cellular production of reactive oxygen species and the antioxidant defense mechanisms. An inflammatory response that occurs in depression leads to a synergy between pro-inflammatory cytokines and oxidative stress. This synergy induces common signal transduction pathways that boost the inflammatory cascade. The object of this study was to assess the concentrations of inflammatory and oxidative status biomediators such as MIP-1α, PMN elastase, MDA, and IL-12 in depressed patients with and without posttraumatic stress disorder (PTSD), and with PTSD alone.
Methods
The number of participants enrolled in the study was 460. Out of them, 420 were determined to be suffering from depression, and 40 (20 males and 20 females) comprised the control group. The subjects were divided into groups, each consisting of 60 participants (30 males and 30 females) with: mild depression (MD), moderate depression (MOD), severe depression (SeD), MD and PTSD (MD + PTSD), MOD and PTSD (MOD + PTSD), SeD and PTSD (Sed + PTSD), and PTSD alone. At 7:00 a.m. all patients had blood samples collected to assess serum concentrations of the studied parameters using the Elisa method.
Results
Depression became more severe as the concentration levels of MIP-1α, PMN elastase, MDA, and IL-12 changed.
Conclusion
Studied parameters can be used as markers of chronic stress in both depression and PTSD, either comorbid or alone, to make an early diagnosis and evaluate disease severity. Revealed changes confirm the presence of a biological response in depression.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016;16(1):22–34.
Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet 2015;2(11):1002–12.
van Zuiden M, Heijnen CJ, van de Schoot R, Amarouchi K, Maas M, Vermetten E, et al. Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study. PLoS One 2011;6(12):e29142.
Merendino RA, Di Pasquale G, De Luca F, Di Pasquale L, Ferlazzo E, Martino G, et al. Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression. Mediators Inflamm 2004;13(3):205–7.
Walton NM, Shin R, Tajinda K, Heusner CL, Kogan JH, Miyake S, et al. Adult neurogenesis transiently generates oxidative stress. PLoS One 2012;7(4):e35264.
Subileau EA, Rezaie P, Davies HA, Colyer FM, Greenwood J, Male DK, et al. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J Neuropathol Exp Neurol 2009;68(3):227–40.
Merendino RA, Di Pasquale G, De Luca F, Di Pasquale L, Ferlazzo E, Martino G, et al. Involvement of fractalkine and macrophage inflammatory protein-1 alpha in moderate-severe depression. Mediators Inflamm 2004;13(3):205–7.
Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396.
Vaváková M, Ďuračková Z, Trebatická J. Markers of oxidative stress and neuroprogression in depression disorder. Oxid Med Cell Longev 2015;2015:898393.
Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology 2015;144(3):365–73.
Hurd TR, DeGennaro M, Lehmann R. Redox regulation of cell migration and adhesion. Trends Cell Biol 2012;22(2):107–15.
Vargas HO, Nunes SO, de Castro MR, Vargas MM, Barbosa DS, Bortolasci CC, et al. Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neurosci Lett 2013;544:136–40.
Bajpai A, Verma AK, Srivastava M, Srivastava R. Oxidative stress and major depression. J Clin Diagn Res 2014;8(12):CC04–7.
Değer O, Bekaroğlu M, Orem A, Orem S, Uluutku N, Soylu C. Polymorphonuclear (PMN) elastase levels in depressive disorders. Biol Psychiatry 1996;39(5):357–63.
Bekaroğlu M, Değer O, Karahan SC, Bilici M, Soylu C, Orem A. Effects of antidepressant treatments on polymorphonuclear elastase levels in patients with depression. J Affect Disord 2000;59(3):175–82.
Han C, Lim YH, Hong YC. The association between oxidative stress and depressive symptom scores in elderly population: a repeated panel study. J Prev Med Public Health 2016;49(5):260–74.
Camkurt MA, Fındıklı E, Izci F, Kurutaş EB, Tuman TC. Evaluation of malondialdehyde, superoxide dismutase and catalase activity and their diagnostic value in drug naıve, first episode, non-smoker major depression patients and healthy controls. Psychiatry Res 2016;238:81–5.
Oh JI, Kaplan S. Redox signaling: globalization of gene expression. EMBO J 2000;19(16):4237–47.
Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(3):676–92.
Scapagnini G, Davinelli S, Drago F, De Lorenzo A, Oriani G. Antioxidants as antidepressants: fact or fiction? CNS Drugs 2012;26(6):477–90.
Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 2008;18(3):230–3.
Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety 2009;26(5):447–55.
Kan AA, van der Hel WS, Kolk SM, Bos IW, Verlinde SA, van Nieuwenhuizen O, et al. Prolonged increase in rat hippocampal chemokine signalling after status epilepticus. J Neuroimmunol 2012;245(1–2):15–22.
Tran PB, Banisadr G, Ren D, Chenn A, Miller RJ. Chemokine receptor expression by neural progenitor cells in neurogenic regions of mouse brain. J Comp Neurol 2007;500(6):1007–33.
Geppert AM, Losy J, Przedpelska-Ober E, Kozubski W. CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer’s disease. Psychiatry Res 2010;176(2–3):261–4.
Capodicasa E, Russano AM, Ciurnella E, De Bellis F, Rossi R, Scuteri A, et al. Neutrophil peripheral count and human leukocyte elastase during chronic lithium carbonate therapy. Immunopharmacol Immunotoxicol 2000;22(4):671–83.
Fleshner M, Frank M, Maier SF. Danger signals and inflammasomes: stress-evoked sterile inflammation in mood disorders. Neuropsychopharmacology 2017;42(1):36–45.
Subbotskaya NV, Sarmanova ZV, Barkhatova AN, Kliushnik TP, Tiganov AS. Clinical and immunological correlations in endogenous depression. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115(4):49–53.
Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin-re-uptake inhibitors. Redox Rep 2003;8(6):365–70.
Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;19(2):89–95.
Gałecki P, Szemraj J, Bieńkiewicz M, Florkowski A, Gałecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009;61(3):436–47.
Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(5):1284–90.
Wei YC, Zhou FL, He DL, Bai JR, Ding H, Wang XY, et al. Oxidative stress in depressive patients with gastric adenocarcinoma. Int J Neuropsychopharmacol 2009;12(8):1089–96.
Sarandol A, Sarandol E, Eker S, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative system. Hum Psychopharmacol 2007;22(2):67–73.
Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by treatments. J Affect Disord 2001;64(1):43–51.
Kim YK, Suh IB, Kim H, Han SC, Lim CS, Choi SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002;7(10):1107–14.
Lee KM, Kim YK. The role of IL-12 of major depressive disorder. Int Immunopharmacol 2006;6(8):1298–304.
Cheng Y, Jope RS, Beurel E. A pre-conditioning stress accelerates increases in mouse plasma inflammatory cytokines induced by stress. BMC Neurosci 2015;16(5):31.
Cassano P, Bui E, Rogers AH, Walton ZE, Ross R, Zeng M, Aus N Z J Psychiatry 2017;51(1):23–31.
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 2017;2:1–15.
Fukuda K. Etiological classification of depression based on the enzymes of tryptophan metabolism. BMC Psychiatry 2014;14(December):372.
Villa A, Vegeto E, Poletti A, Maggi A. Estrogens, neuroinflammation, and neurodegeneration. Endocr Rev 2016;37(4):372–402.
Wise PM, Suzuki S, Brown CM. Estradiol: a hormone with diverse and contradictory neuroprotective actions. Dialogues Clin Neurosci 2009;11(3):297–303.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogłodek, E.A. Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without posttraumatic stress disorder. Pharmacol. Rep 70, 110–118 (2018). https://doi.org/10.1016/j.pharep.2017.08.008
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2017.08.008